Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Adsorbed Cell-free DTaP (Three-component) Vaccine in Children
NCT05189548Phase 2Unknown
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of diphtheria + tetanus + acellular pertussis vaccine in diphtheria, Tetanus, pertussis, sponsored by Changchun BCHT Biotechnology Co.. Status: unknown.
02
Drugs
diphtheria + tetanus + acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT05189548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189548.